Core Insights - The company Yipinhong (300723) has received approval for three new drugs from the National Medical Products Administration, enhancing its product pipeline in the pediatric and chronic disease medication sectors [1][2] Drug Approvals - The three approved drugs include: - Esomeprazole magnesium enteric-coated suspension, indicated for gastroesophageal reflux disease and H. pylori eradication, with a projected sales scale of approximately 2.243 billion yuan in 2024 [1] - Ketoconazole sustained-release tablets, aimed at peripheral vascular diseases, with an expected sales scale of around 1.426 billion yuan in 2024 [1] - Compound polyethylene glycol (3350) electrolyte powder, for treating chronic constipation in children, with a projected sales scale of about 1.108 billion yuan in 2024 [2] Market Positioning - The approval of these drugs signifies the company's qualification to market these products domestically, thereby enriching its offerings in the pediatric and chronic disease medication fields and enhancing its competitive edge [2] Recent Developments - A week prior, the company announced the approval of a drug for treating mild to moderate Alzheimer's symptoms, with an expected sales scale of approximately 100 million yuan in 2024 [2] - The company is also advancing its innovative gout drug, AR882, which has completed the target enrollment of 680 patients in its domestic Phase III clinical trial [2][3] Clinical Trial Results - Data from completed global Phase II trials for AR882 indicate effective reduction of serum uric acid (sUA) and high rates of complete dissolution of gout stones in patients, providing a promising oral treatment option for chronic gout patients [3]

公司要闻： 国邦医药（605507）：公司发布公告，公司拟对董事、高管在内的270名员工实施员工持股计划，拟筹 集资金总额不超过1.85 亿元，涉及的股票总数不超过股本总额的10%，存续期为24 个月，锁定期为12 个月。 泰恩康（301263）：公司发布公告，子公司山东华铂凯盛于近日收到国家药品监督管理局签发的巴瑞替 尼片《药品注册证书》，经审查，本品符合药品注册的有关要求，批准注册。 一品红（300723）：公司发布公告，子公司广州一品红于近日收到国家药品监督管理局核准签发的艾司 奥美拉唑镁肠溶干混悬剂《药品注册证书》，，经审查，本品符合药品注册的有关要求，批准注册。 恩华药业（002262）：公司发布公告，近日收到国家药品监督管理局签发的盐酸羟考酮缓释片《药品注 册证书》，经审查，本品符合药品注册的有关要求，批准注册。 市场表现： 2025 年11 月28 日，医药板块涨跌幅+0.14%，跑输沪深300 指数0.11pct，涨跌幅居申万31 个子行业第27 名。各医药子行业中，医疗设备(+1.53%)、医院（+0.95%)、其他生物制品(+0.70%)表现居前，线下药 店（-0.55%）、疫苗(-0.4 ...

Core Points - The company Yipinhong announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received the drug registration certificate for Esomeprazole Magnesium Enteric-coated Suspension from the National Medical Products Administration [2] Company Summary - Yipinhong's subsidiary has successfully obtained regulatory approval for a new drug, which may enhance its product portfolio and market presence [2] - The approval of Esomeprazole Magnesium Enteric-coated Suspension indicates the company's commitment to expanding its offerings in the pharmaceutical sector [2] Industry Summary - The approval from the National Medical Products Administration reflects the regulatory environment's support for new drug development in the pharmaceutical industry [2] - This development may signal potential growth opportunities within the gastrointestinal treatment market, as Esomeprazole is commonly used for acid-related disorders [2]

格隆汇11月28日丨一品红(300723.SZ)公布，全资子公司广州一品红制药有限公司于近日收到国家药品 监督管理局核准签发的关于艾司奥美拉唑镁肠溶干混悬剂的《药品注册证书》，艾司奥美拉唑是一种质 子泵抑制剂，是奥美拉唑的S-异构体，通过特异性地抑制胃壁细胞H+-K+ATP酶而阻断胃酸分泌的最后 步骤。艾司奥美拉唑在胃壁细胞的酸性环境中转化为活性成份，对基础胃酸分泌和受刺激后的胃酸分泌 均产生抑制。 ...

智通财经APP讯，一品红(300723.SZ)公告，公司全资子公司广州一品红制药有限公司于近日收到国家药 品监督管理局核准签发的关于艾司奥美拉唑镁肠溶干混悬剂的《药品注册证书》。艾司奥美拉唑是一种 质子泵抑制剂，是奥美拉唑的S-异构体，通过特异性地抑制胃壁细胞H+-K+ATP酶而阻断胃酸分泌的最 后步骤。艾司奥美拉唑在胃壁细胞的酸性环境中转化为活性成份，对基础胃酸分泌和受刺激后的胃酸分 泌均产生抑制。 ...

一品红（300723）(300723.SZ)公告，公司全资子公司广州一品红制药有限公司于近日收到国家药品监 督管理局核准签发的关于艾司奥美拉唑镁肠溶干混悬剂的《药品注册证书》。艾司奥美拉唑是一种质子 泵抑制剂，是奥美拉唑的S-异构体，通过特异性地抑制胃壁细胞H+-K+ATP酶而阻断胃酸分泌的最后步 骤。艾司奥美拉唑在胃壁细胞的酸性环境中转化为活性成份，对基础胃酸分泌和受刺激后的胃酸分泌均 产生抑制。 ...